Kezar Life Sciences Analyst Ratings
Kezar Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 1751.85% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 10/05/2023 | — | JonesTrading | Downgrades | Buy → Hold | |
| 09/25/2023 | 1751.85% | HC Wainwright & Co. | $18 → $20 | Maintains | Buy |
| 08/11/2023 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 08/11/2023 | 1566.67% | HC Wainwright & Co. | $19 → $18 | Maintains | Buy |
| 05/12/2023 | 1659.26% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/12/2023 | 1103.7% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 03/16/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/16/2023 | 1844.44% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 01/03/2023 | 1196.3% | Wells Fargo | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 1844.44% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 06/28/2022 | 1474.07% | Wells Fargo | $13 → $17 | Maintains | Overweight |
| 05/13/2022 | 1103.7% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 05/04/2022 | 1196.3% | Wells Fargo | $19 → $14 | Maintains | Overweight |
| 03/18/2022 | 1937.04% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 12/08/2021 | 1659.26% | Wells Fargo | → $19 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 1751.85% | HC Wainwright & Co. | $12 → $20 | Maintains | Buy |
| 07/20/2021 | 1196.3% | JonesTrading | → $14 | Initiates Coverage On | → Buy |
| 06/04/2020 | 1011.11% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 05/05/2020 | 733.33% | HC Wainwright & Co. | $15 → $9 | Reiterates | → Buy |
| 03/13/2020 | 1566.67% | Wells Fargo | $30 → $18 | Maintains | Overweight |
| 07/29/2019 | 1288.89% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月12日 | 1751.85% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 10/05/2023 | - | Jones Trading | 評級下調 | 購買→Hold | |
| 09/25/2023 | 1751.85% | HC Wainwright公司 | $18→$20 | 維護 | 買 |
| 2023年08月11日 | - | 富國銀行 | 評級下調 | 超重→等重 | |
| 2023年08月11日 | 1566.67% | HC Wainwright公司 | $19→$18 | 維護 | 買 |
| 2023年05月12日 | 1659.26% | HC Wainwright公司 | $21→$19 | 維護 | 買 |
| 2023年05月12日 | 1103.7% | 富國銀行 | $14→$13 | 維護 | 超重 |
| 03/16/2023 | - | 威廉·布萊爾 | 評級下調 | 跑贏→市場表現 | |
| 03/16/2023 | 1844.44% | HC Wainwright公司 | →$21 | 重申 | →購買 |
| 01/03/2023 | 1196.3% | 富國銀行 | $17→$14 | 維護 | 超重 |
| 2022年08月12日 | 1844.44% | HC Wainwright公司 | $20→$21 | 維護 | 買 |
| 2022/06/28 | 1474.07% | 富國銀行 | $13→$17 | 維護 | 超重 |
| 2022年05月13日 | 1103.7% | 富國銀行 | $14→$13 | 維護 | 超重 |
| 05/04/2022 | 1196.3% | 富國銀行 | $19→$14 | 維護 | 超重 |
| 03/18/2022 | 1937.04% | HC Wainwright公司 | $20→$22 | 維護 | 買 |
| 12/08/2021 | 1659.26% | 富國銀行 | →$19 | 開始承保 | →超重 |
| 2021年11月16日 | 1751.85% | HC Wainwright公司 | $12→$20 | 維護 | 買 |
| 07/20/2021 | 1196.3% | Jones Trading | →$14 | 開始承保 | →購買 |
| 06/04/2020 | 1011.11% | HC Wainwright公司 | $9→$12 | 維護 | 買 |
| 05/05/2020 | 733.33% | HC Wainwright公司 | $15→$9 | 重申 | →購買 |
| 03/13/2020 | 1566.67% | 富國銀行 | $30→$18 | 維護 | 超重 |
| 2019年07月29日 | 1288.89% | HC Wainwright公司 | →$15 | 開始承保 | →購買 |
What is the target price for Kezar Life Sciences (KZR)?
Kezar生命科學公司(KZR)的目標價是多少？
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $20.00 expecting KZR to rise to within 12 months (a possible 1751.85% upside). 10 analyst firms have reported ratings in the last year.
凱撒生命科學公司(納斯達克代碼：KZR)的最新目標價是由HC Wainwright&Co.於2023年10月12日報道的。這家分析公司將目標價定為20美元，預計KZR將在12個月內上漲至(可能上漲1751.85%)。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
Kezar Life Science(KZR)的最新分析師評級是多少？
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by HC Wainwright & Co., and Kezar Life Sciences reiterated their buy rating.
凱撒生命科學(納斯達克代碼：KZR)的最新分析師評級由HC Wainwright&Co.提供，凱撒生命科學重申其買入評級。
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Kezar Life Science(KZR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Kezar Life Science的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Kezar生命科學的上一次評級是在2023年10月12日提交的，所以你應該預計下一次評級將在2024年10月12日左右的某個時候提供。
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
分析師對Kezar Life Science(KZR)的評級正確嗎？
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a reiterated with a price target of $0.00 to $20.00. The current price Kezar Life Sciences (KZR) is trading at is $1.08, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Kezar Life Science(KZR)評級被重申，目標價在0.00美元至20.00美元之間。Kezar生命科學公司(KZR)目前的股價為1.08美元，在分析師的預測範圍內。